Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and the wider pharma industry. They also offer insights into Alter Pharma’s planned launch of generic medicines in the US market and their strategy for success.
Nowadays, there are a substantial number of drugs unavailable in Belgium, but readily available in other European countries. Through parallel imports, we are able to safely repackage and make these medicines available to Belgian patients
